Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Procalcitonin in Cirrhotic Patients at High Risk for Sepsis

This study has been completed.
Information provided by (Responsible Party):
Prof. Facchinetti Fabio, University of Modena and Reggio Emilia Identifier:
First received: April 13, 2012
Last updated: NA
Last verified: April 2012
History: No changes posted
Infections are frequent life-threatening events in patients with cirrhosis, occurring at least in 35% of hospitalized patients and accounting for 20% of inpatients death. Among cirrhotics, ascitic patients have the highest risk of death for sepsis. At the admission, no clear-cut clinical and biochemical features are helpful in diagnosing and prognostically stratifying those patients with sepsis. Procalcitonin (PCT)is a breakthrough marker presenting high sensibility and specificity in diagnosing bacterial infections in different clinical settings. The purpose of this study is to evaluate PCT as a diagnostic and prognostic tool for sepsis in hospitalized cirrhotic patients with ascitic decompensation.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Role of Procalcitonin (PCT) for the Diagnosis of Sepsis in Ascitic Cirrhotic Patients

Resource links provided by NLM:

Further study details as provided by University of Modena and Reggio Emilia:

Biospecimen Retention:   Samples Without DNA

Enrollment: 75
Study Start Date: October 2009
Study Completion Date: September 2011
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Decompensated cirrhotic patients
Cirrhotic patients presenting with clinically detectable ascites (Grade 2 o Grade 3)


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All ascitic cirrhotic patients admitted to our third level Liver Unit.

Inclusion Criteria:

  • liver cirrhosis regardless of aetiology
  • clinically relevant ascitic decompensation at time of hospital admission

Exclusion Criteria:

  • high haematic ascites
  • ongoing antimicrobial therapy or stopped less than 7 days before admission
  • last hospital discharge within 7 days
  • surgery or trauma within 30 days from enrolment
  • hepatocellular carcinoma out of Milan criteria
  • extra hepatic malignancies
  • immunodeficiency syndrome
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01578226

Gastroenterology Unit - University Hospital of Modena
Modena, Italy, 41124
Sponsors and Collaborators
Prof. Facchinetti Fabio
Principal Investigator: Filippo Schepis, MD University of Modena and Reggio Emilia
  More Information

Responsible Party: Prof. Facchinetti Fabio, PRS Admin, University of Modena and Reggio Emilia Identifier: NCT01578226     History of Changes
Other Study ID Numbers: PCTCIRR
Study First Received: April 13, 2012
Last Updated: April 13, 2012

Keywords provided by University of Modena and Reggio Emilia:
Bacterial infection

Additional relevant MeSH terms:
Systemic Inflammatory Response Syndrome
Pathologic Processes processed this record on May 22, 2017